3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 1/2
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Metastatic Castration-Resistant Prostate Cancer
1
Kidney Neoplasms
1
Interventions
pembrolizumab
21
lenvatinib
8
Paclitaxel
5
patritumab deruxtecan
3
enfortumab vedotin
2
belzutifan
2
Tretinoin
2
Surgical Procedures, Operative
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Carboplatin
2
Capecitabine
2
tremelimumab
1
trametinib
1
poly ICLC
1
epacadostat
1
efineptakin alfa
1
durvalumab
1
dabrafenib
1
Ramucirumab
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Pemetrexed
1
Levoleucovorin
1
Immunotherapy
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
belzutifan
×
Clear all
NCT04626479
2026-05-18
MK-3475-03A
Merck Sharp & Dohme LLC
Phase 1/2
Active not recruiting
400 enrolled
NCT04626518
2026-05-06
KEYMAKER-U03
Merck Sharp & Dohme LLC
Phase 1/2
Active not recruiting
370 enrolled